RhabdomyosarcomaPhase 2NCT00464620
Trial of Dasatinib in Advanced Sarcomas
A Phase 2 study testing Dasatinib in people with Rhabdomyosarcoma and Malignant Peripheral Nerve Sheath Tumors, run by Sarcoma Alliance for Research through Collaboration at 20 sites in United States.
Trial summary
This study will examine the response rate and the 6-month progression-free survival rates of subjects with advanced sarcoma treated with dasatinib. Read more about this study
- Who is it for?
- Ages 13 years and older
- Conditions the study is for
- Rhabdomyosarcoma, Malignant Peripheral Nerve Sheath Tumors, Chondrosarcoma
- What is being tested?
- Dasatinib
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 366 participants
- Where
- 20 sitesUnited States
- Study dates
- May 2007to May 2017
- Phase
- Phase 2
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 13 years and older
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- Unresectable, recurrent, or metastatic histologically-confirmed soft tissue or bone sarcoma of one of the following subtypes:
- Leiomyosarcoma --* NO LONGER ELIGIBLE*
- Liposarcoma--* NO LONGER ELIGIBLE*
- Malignant fibrous histiocytoma (MFH)/pleomorphic undifferentiated sarcoma--* NO LONGER ELIGIBLE*
- Rhabdomyosarcoma --* NO LONGER ELIGIBLE*
- Malignant peripheral nerve sheath tumor (MPNST) --* NO LONGER ELIGIBLE*
Show all 32Show fewer
- Osteosarcoma (skeletal or extraosseous)--* NO LONGER ELIGIBLE*
- Ewing's --* NO LONGER ELIGIBLE*
- Chondrosarcoma
- Alveolar soft part sarcoma
- Chordoma
- Epithelioid sarcoma
- Giant cell tumor of bone
- Hemangiopericytoma/solitary fibrous tumor
- Gastrointestinal Stromal Tumor (GIST) --* NO LONGER ELIGIBLE*
- Documentation that subjects with leiomyosarcoma, liposarcoma, osteosarcoma, Ewing's, MPNST, rhabdomyosarcoma or MFH have received, not been eligible for or refused at least one prior chemotherapy regimen before participation in the dasatinib study. Subjects with GIST must have received or been intolerant to imatinib; prior treatment with other agents including sunitinib is not required.Neoadjuvant/adjuvant chemotherapy qualifies as prior therapy.
- Subjects must have unidimensionally measurable lesion(s) either by x-ray, computed tomography (CT), magnetic resonance imaging (MRI) or physical examination documented within 30 days prior to registration.
- Prior radiation will be allowed. More than two weeks should have elapsed since the administration of the last fraction of radiation therapy, and subjects must have recovered from grade 2 or higher associated toxicities. Measurable lesions, which are selected as target lesions, must be outside previously radiated fields or have documented progression no sooner than 6 weeks after completion of radiation.
- More than 2 weeks must have elapsed since the subject has received any prior systemic chemotherapy (6 weeks for mitomycin C), and the patient should have recovered from toxicities to the baseline prior to the last course of chemotherapy.
- Adequate hematologic function within 14 days prior to registration.
- Prothrombin Time (PT) (or INR) and Partial Thromboplastin Time (PTT) ≤ 1.5 times the institutional upper limit of normal (ULN) within 14 days prior to registration.
- Serum creatinine ≤ 2.0 times the institutional ULN within 14 days prior to registration.
- Serum magnesium, potassium and adjusted (or ionized) calcium ≥ the institutional lower limit of normal (LLN). (Supplementation of electrolytes prior to screening is allowed).
- Left ventricular ejection fraction ≥ 45% measured by echocardiogram or multiple gated acquisition (MUGA) within 30 days prior to registration (but must be performed after the last dose of an anthracycline) for subjects who have received an anthracycline (e.g. doxorubicin, epirubicin) or have a medical history of cardiac disease. The measurement of left ventricular ejection fraction is not required of subjects whom have not received cardiotoxic chemotherapy (e.g. anthracycline) and do not have a medical history of cardiac disease.
- Sexually active women and men of childbearing potential must agree to use an effective method of birth control during the course of the study and for up to 3 months following the last dose of the study drug, in a manner such that risk of pregnancy is minimized. Surgical sterilization, intrauterine device or barrier method (e.g. condom and/or diaphragm with spermicidal agents) are acceptable forms of birth control.
- Women of childbearing potential must have a negative pregnancy test (urine or serum) within 7 days prior to treatment. A pregnancy test is not required for registration. Women who have not menstruated for more than 2 years will be considered postmenopausal, thus not of childbearing potential.
- Eastern Cooperative Oncology Group (ECOG) performance score 0, 1 or 2.
- Weight ≥ 50 kg because there is limited experience with dasatinib in subjects weighing less than 50 kg.
- ≥13 years of age Minors will be required to sign an assent document prior to treatment.
- Subjects must be able to swallow whole tablets.
- Subjects must be informed of the investigational nature of the study and provide written, informed consent and authorization to release protected health information using a document(s) approved by the investigator's institution.
- A paraffin block, either from a previous surgery or recent biopsy, should be available for correlative studies. If a block of tumor is not available, at least 8 unstained slides of tumor sample, 1 H\&E and three (3) 15 micron-thick sections in an eppendorf tube for DNA extraction from a representative portion of the sarcoma may be substituted after discussion with and approval from the study Principal Investigator.
Who cannot join
- Subjects who are curable by conventional multidisciplinary management.
- Subjects with symptomatic central nervous system metastasis.
- Women who are pregnant or nursing/breastfeeding.
- History of significant bleeding disorder unrelated to cancer, including:
- Diagnosed congenital bleeding disorders (e.g., von Willebrand's disease)
- Diagnosed acquired bleeding disorder within one year (e.g., acquired anti-factor VIII antibodies)
Show all 18Show fewer
- Subjects currently taking medications that inhibit platelet function (i.e., aspirin, dipyridamole, epoprostenol, eptifibatide, clopidogrel, cilostazol, abciximab, ticlopidine, and any non-steroidal anti-inflammatory drug) because of a potential increased risk of bleeding from dasatinib.
- Subjects currently taking anticoagulants (warfarin, heparin/low molecular weight heparin [e.g., danaparoid, dalteparin, tinzaparin, enoxaparin]) because of a potential increased risk of bleeding from dasatinib.
- Diagnosis of unstable angina or myocardial infarction within 6 months of study entry.
- Subjects currently taking one or more of the following drugs that are generally accepted to have a risk of causing Torsades de Pointes:
- Quinidine, procainamide, disopyramide
- Amiodarone, sotalol, ibutilide, dofetilide
- Erythromycins, clarithromycin
- Chlorpromazine, haloperidol, mesoridazine, thioridazine, pimozide
- Cisapride, bepridil, droperidol, methadone, arsenic, chloroquine, domperidone, halofantrine, levomethadyl, pentamidine, sparfloxacin, lidoflazine.
- Diagnosed or suspected congenital long QT syndrome.
- Prolonged corrected QT (QTc) interval on pre-entry electrocardiogram (> 450 msec) within 30 days prior to study registration.
- Subjects unable or unwilling to suspend treatment with bisphosphonates for at least the first 8 weeks of treatment with study drug because of the risk of hypocalcemia caused by dasatinib.
Trial locations and contacts
20 sites in 1 country.
20 sites in 1 country
United States20 sites
University of Michigan
Ann Arbor, Michigan, 48109
Winship Cancer Institute at Emory University
Atlanta, Georgia, 30308
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland, 21231
Massachusetts General Hospital
Boston, Massachusetts, 02114
Dana Farber Cancer Institute
Boston, Massachusetts, 02115
Kootenai Cancer Center
Coeur d'Alene, Idaho, 83814
City of Hope
Duarte, California, 91010
MD Anderson
Houston, Texas, 77030
Indiana University Cancer Center
Indianapolis, Indiana, 46202
University of Iowa Hospitals and Clinics
Iowa City, Iowa, 52242
Arkansas Children's Hospital
Little Rock, Arkansas, 72202
Cedars-Sinai Outpatient Cancer Center
Los Angeles, California, 90048
Nebraska Methodist Hospital
Omaha, Nebraska, 68114
Stanford University
Palo Alto, California, 94304
Oncology Specialists
Park Ridge, Illinois, 60068
Pennsylvania Oncology Hematology Associates
Philadelphia, Pennsylvania, 19106
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111
University of Pittsburgh Cancer Institute
Pittsburgh, Pennsylvania, 15232
Sarcoma Oncology Center
Santa Monica, California, 90403
Washington Cancer Institute
Washington D.C., District of Columbia, 20010
About this study
Official title: A Phase II Trial of Dasatinib in Advanced Sarcomas
This study will examine the response rate and the 6-month progression-free survival rates of subjects with advanced sarcoma treated with dasatinib.
Read the detailed description
Further details provided by SARC (Sarcoma Alliance for Research through Collaboration):
Treatment: Subjects take Dasatinib twice daily by mouth for 28 days per 28 day cycle.
Subjects will be seen for interim medical history, physical exam and laboratory studies prior to each cycle. Subjects will undergo tumor imaging every 2 months (8 weeks) for the first 6 months and approximately every 3 months thereafter while on treatment.
A blood sample for collection of specimens with which to later study serum level of Dasatinib and effects on biomarkers of drug activity will be obtained approximately 2 to 4 weeks after the start of treatment.
Central collection of archival tumor with which to later study the frequency of expression and/or mutation of kinases inhibited by dasatinib will occur.
Subjects will be followed for approximately every 3 months until 2 years from registration and then approximately yearly until 5 years from registration.
- Conditions
- Rhabdomyosarcoma, Malignant Peripheral Nerve Sheath Tumors, Chondrosarcoma, Sarcoma, Ewing's, Sarcoma, Alveolar Soft Part, Chordoma
- Being tested
- Dasatinib
- Keywords
- Dasatinib, Rhabdomyosarcoma, Malignant peripheral nerve sheath tumor, Chondrosarcoma, Ewing's, Alveolar soft part sarcoma (ASPS), Chordoma, Epithelioid sarcoma, Giant cell tumor of bone, Hemangiopericytoma/solitary fibrous tumor, Gastrointestinal Stromal Tumor (GIST)
- Medical subject headings
- Rhabdomyosarcoma, Neurofibrosarcoma, Chondrosarcoma, Sarcoma, Ewing, Sarcoma, Alveolar Soft Part, Chordoma, Sarcoma, Giant Cell Tumor of Bone
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
DasatinibDrug
oral agent, continuous dosing, Cycles = 28 days
| Study group | Role | What they receive |
|---|---|---|
| Dasatinib, 70 mg, twice daily | Experimental | Patients take 70 mg of Dasatinib, twice daily, for 28 day cycles Receives: Drug: Dasatinib |
What is being measured
The primary outcome is the main question the study is designed to answer.
Response Rate: Number of Participants With Objective Tumor Response
Assessment of objective tumor response for response rate with MRI or CT using Choi criteria: Complete Remission (CR) Complete disappearance of all measurable and evaluable disease for at least 4 weeks; Partial Remission (PR) A 10% or greater decrease from the baseline in the sum of the largest diameters of all measurable target lesions.
Measured: Up to 24 months
6 Month Progression-free Survival Rate of "Indolent" Sarcomas Treated With Dasatinib
Estimate the 6 month progression-free survival rate of "indolent" sarcomas treated with dasatinib. Progression is defined using Choi criteria, as a 10% or greater increase in the sum of all measurable target lesions over the smallest sum observed (over baseline if no decrease) using the same techniques as baseline, or clear worsening of any evaluable disease, or unequivocal reappearance of any lesion which had disappeared, or appearance of any new lesions of greater than double slice thickness in size, or any new or enlarging solid nodule in a previously hypodense treated mass.
Measured: At 6 months
6 Month Progression-free Survival Rate of Gastrointestinal Stromal Tumors (GIST)
To estimate the 6 month progression-free survival rate of gastrointestinal stromal tumors (GIST). Progression is defined using Choi criteria, as a 10% or greater increase in the sum of all measurable target lesions over the smallest sum observed (over baseline if no decrease) using the same techniques as baseline, or clear worsening of any evaluable disease, or unequivocal reappearance of any lesion which had disappeared, or appearance of any new lesions of greater than double slice thickness in size, or any new or enlarging solid nodule in a previously hypodense treated mass.
Measured: 6 months
Secondary outcomes (10)
Median Time-to-progression of Subjects With GIST Treated With Dasatinib.
To estimate the median time-to-progression of subjects with GIST treated with dasatinib.
Measured: Up to 30 months
Overall Survival Rates at 2 and 5 Years From Registration of Subjects Treated With Dasatinib.
To estimate the overall survival rates at 2 and 5 years from registration of subjects treated with dasatinib.
Measured: At 2 and 5 years
Median Time-to-progression of Subjects With "Indolent" Sarcomas Treated With Dasatinib.
To estimate the median time-to-progression of subjects with "indolent" sarcomas treated with dasatinib.
Measured: Up to 24 months
6 Month Progression-free Survival Rate of Subjects Enrolled in the Aggressive Subtype.
To estimate the 6 month progression-free survival rate of subjects with leiomyosarcoma, liposarcoma, osteosarcoma including high-grade chondrosarcomas, Ewing's sarcoma, Malignant fibrous histiocytoma (MFH), rhabdomyosarcoma and MPNST treated with dasatinib.
Measured: At 6 months
Median Time-to-progression of Subjects Enrolled in the Aggressive Subtype.
To estimate the median time-to-progression of subjects with leiomyosarcoma, liposarcoma, osteosarcoma including high-grade chondrosarcomas, Ewing's sarcoma, MFH, rhabdomyosarcoma and MPNST treated with dasatinib.
Measured: Up to 37 weeks
Overall Survival Rates at 2 and 5 Years From Registration of Subjects Enrolled in the Aggressive Subtype Treated With Dasatinib.
To estimate the overall survival rates at 2 and 5 years from registration of subjects enrolled in the aggressive subtype treated with dasatinib.
Measured: At 2 and 5 years
Uni-dimensional and Bi-dimensional Tumor Size, Tumor Volumes and Tumor Average Density Determined by Computer-aided Automated Detection in a Subset of Subjects With Tumor Predominately Involving the Lung
To prospectively collect uni-dimensional and bi-dimensional tumor size, tumor volumes and tumor average density determined by computer-aided automated detection in a subset of subjects with tumor predominately involving the lung
Measured: Up to 37 weeks
Plasma Level of Dasatinib and Inhibition of SRC and/or Focal Adhesion Kinase (FAK) in Peripheral Blood Mononuclear Cells
Obtain blood samples to characterize plasma level of dasatinib and inhibition of SRC and/or FAK in peripheral blood mononuclear cells 2 hours after ingestion of drug at 2-4 weeks from the start of treatment if activity of the drug in a sarcoma subtype warrants further study.
Measured: 2-4 weeks from start of treatment
Number of Participants With Tumors With Kinase Expression
Obtain tumor tissue for creation of tissue microarrays to examine the frequency of kinase expression such as SRC and/or FAK in leiomyosarcoma, liposarcoma, osteosarcoma, MFH, rhabdomyosarcoma, MPNST, chondrosarcoma, Ewing's, Alveolar soft part sarcoma (ASPS), chordoma, epithelioid sarcoma, giant cell tumor of bone, hemangiopericytoma, and GIST if activity of the drug in a subtype warrants further study. The outcome measure demonstrates the number of participants who had tissue that was able to generate tissue microarray for kinase expression.
Measured: Up to 37 weeks
Number of Participants With Tumors With Mutations in Kinases
Obtain tumor tissue to examine the frequency of mutations in kinases such as PDGFR in leiomyosarcoma, liposarcoma, osteosarcoma, MFH, rhabdomyosarcoma, MPNST, chondrosarcoma, Ewing's, ASPS, chordoma, epithelioid sarcoma, giant cell tumor of bone, hemangiopericytoma and GIST if activity of the drug in a subtype warrants further study. The outcome measure demonstrates the tissue that was able to generate tissue microarray for PDGFR analysis.
Measured: Up to 37 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Apr 2007 (estimated)
- Study startMay 2007
- Primary completionDec 2016
- Study completionMay 2017
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for RhabdomyosarcomaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 366 participants (actual)
Sponsor and investigators
- Lead sponsor
- Sarcoma Alliance for Research through Collaboration
- Sponsor type
- University, hospital or other
- Collaborators
- Bristol-Myers Squibb
- Responsible party
- Sponsor
- Investigators
- Scott Schuetze, MD, PhD, Principal investigator, University of Michigan
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00464620
- Sponsor's protocol ID
- SARC009
- Status last verified
- Oct 2018
- First submitted
- 20 Apr 2007
- Last updated
- 23 Nov 2018
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes